Novartis, Roche back French gene therapy start-up Vivet – Reuters
Endpoints News |
Novartis, Roche back French gene therapy start-up Vivet
Reuters Gene therapy seeks to cure rare genetic diseases by offering a one-time fix of a faulty DNA. There is rising interest in the field, even though the Western world's first gene therapy for an ultra-rare condition is being pulled from the market due to … French Gene Therapy Biotech Raises a Huge €37.5M in Series A GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech Vivet Therapeutics Raises €37.5 Million in Series A Financing Round to Advance Novel Gene Therapies for Treating … |
